Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
Induced pluripotent stem (iPS) cells offer tremendous opportunity for the creation of autologous cellular therapies, in which gene correction or the avoidance of immune response issues are desirable. In addition, iPS cells avoid the ethical concerns raised by the sourcing of human embryonic stem cells (hESCs) from embryos. iPS cells share many characteristics with hESCs and it is anticipated that existing experience with hESCs will translate to rapid progress in moving iPS cell-derived products toward clinical trials. While the potential clinical value for these products is considerable, the nature of current manufacturing paradigms for autologous iPS cell products raises considerable regulatory concerns. Here, the regulatory challenges posed by autologous iPS cell-derived products are examined. We conclude that there will be considerable regulatory concerns primarily relating to reproducibility of the manufacturing process and safety testing within clinically limited time constraints. Demonstrating safety of the final cell product in an autologous setting will be the single greatest obstacle to progressing autologous iPS cell-based therapies into the clinic.
Carpenter
Melissa K
MK
Center for Applied Technology Development, Beckman Research Institute of City of Hope, Duarte, CA, USA. m_carpenter@mac.com
Couture
Larry A
LA
D064987:Cell- and Tissue-Based Therapy / Q000941:ethics / Q000592:standards / Q000639:trends; D004345:Drug Industry / Q000331:legislation & jurisprudence; D017408:Guidelines as Topic; D006291:Health Policy; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000637:transplantation*; D023822:Tissue Engineering; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*